Sympathetic neural patterns and transduction in obesity-associated hypertension
肥胖相关高血压的交感神经模式和转导
基本信息
- 批准号:10877436
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:Action PotentialsAdrenergic AgentsAdrenergic alpha-AntagonistsAdultAgeAnimal ModelCardiovascular DiseasesCardiovascular systemChronicDataGoalsHeart failureHigh PrevalenceHumanHypertensionHypoxiaIndividualInvestigationMeasuresMediatingMetabolic DiseasesNational Heart, Lung, and Blood InstituteNorepinephrineObesityObesity EpidemicParticipantPatientsPatternPeripheralPhysiologicalPsyche structureRecommendationReflex actionResearchRestRodent ModelSignal TransductionSleep Apnea SyndromesStressTestingVasoconstrictor Agentsadult obesityalpha-adrenergic receptorattributable mortalityblood pressure regulationhypertensiveneural patterningneuropeptide Yneurotransmissionneurovascularnew therapeutic targetnovel therapeutic interventionobese patientspatient populationpharmacologicphysiologic stressorreceptorrecruitresponsetherapeutically effectivevasoconstrictionworking group
项目摘要
PROJECT SUMMARY
Cardiovascular mortality attributable to hypertension (HTN) has increased by more than 10 percent in the last
decade, due in part to the escalating obesity epidemic. Effective therapeutic options for HTN are limited and
despite a high prevalence of multi-pharmacological approaches, more than 50% of hypertensive individuals
remain uncontrolled. As such, studies that advance understanding of basic mechanisms of blood pressure
regulation in humans are needed to identify novel therapeutic targets. Exaggerated sympathetic nervous activity
(SNA) and vasoconstriction are hallmark features of many cardiovascular diseases including obesity-associated
HTN (Ob-HTN). Causes of exaggerated sympathetic vasoconstriction are unclear, however recent advances in
quantification of sympathetic activity have uncovered unique action potential patterns that influence the
peripheral vasoconstrictor response to stress. In animal models, sympathetic firing patterns during stress
increase co-release of the potent vasoconstrictor neuropeptide Y (NPY) in conjunction with norepinephrine,
causing a shift in the mechanisms of vasoconstriction towards NPY-mediated signaling. NPY causes
vasoconstriction via activation of NPY 1 receptors (Y1R), and facilitates α-adrenergic mediated signaling causing
exaggerated sympathetic vasoconstriction. We hypothesize that physiological stressors like obesity and hypoxia
alter sympathetic action potential patterns that cause vasoconstriction to rely on NPY-mediated signaling. The
overall aim of this proposal is to 1) identify how sympathetic action potential patterns change in response to
chemoreflex and mental stress 2) to assess the impact of action potential patterns on mechanisms of
vasoconstriction in healthy adults and in patients with Ob-HTN. To accomplish these goals, we will we will assess
beat-by-beat vasoconstriction in response to endogenous bursts of SNA during pharmacological manipulation
of α-adrenergic receptors and Y1Rs to determine the mechanisms of exaggerated sympathetic vasoconstriction
during chemoreflex/mental stress in healthy adults and Ob-HTN patients. We anticipate that these investigations
will 1) further understanding of the basic signaling mechanisms responsible for neurovascular transduction in
humans including the interaction between action potential patterns, neurotransmission and vasoconstriction 2)
identify new mechanisms underlying exaggerated neurovascular transduction in Ob-HTN and 3) provide
avenues for research in other patient populations characterized by elevated SNA and exaggerated
vasoconstriction including sleep apnea, metabolic disease, and heart failure.
项目摘要
在过去的10年里,高血压(HTN)导致的心血管死亡率增加了10%以上。
十年,部分原因是肥胖症的流行。HTN的有效治疗选择有限,
尽管多种药物治疗的流行率很高,但超过50%的高血压患者
保持不受控制。因此,推进对血压基本机制的理解的研究
需要在人类中进行调节以鉴定新的治疗靶点。交感神经活动增强
(SNA)和血管收缩是许多心血管疾病(包括肥胖相关疾病)的标志性特征
HTN(Ob-HTN)。交感神经血管收缩过度的原因尚不清楚,但最近的进展,
交感神经活动的量化已经揭示了影响交感神经活动的独特动作电位模式。
外周血管收缩反应的压力。在动物模型中,压力下交感神经放电模式
增加强效血管收缩神经肽Y(NPY)与去甲肾上腺素的共同释放,
导致血管收缩机制向NPY介导的信号传导转变。NPY病因
通过激活NPY 1受体(Y1 R)引起血管收缩,并促进α-肾上腺素能介导的信号传导,
交感神经血管收缩过度我们假设生理压力如肥胖和缺氧
改变交感神经动作电位模式,导致血管收缩依赖于NPY介导的信号传导。的
该提议的总体目标是:1)识别交感神经动作电位模式如何响应于
化学反射和精神压力2)评估动作电位模式对
健康成人和Ob-HTN患者的血管收缩。为了实现这些目标,我们将评估
药物操作过程中SNA内源性爆发引起的逐搏血管收缩
α-肾上腺素能受体和Y1受体的测定,以确定过度交感血管收缩的机制
在健康成人和Ob-HTN患者的化学反射/精神应激期间。我们预计这些调查
1)进一步了解神经血管转导的基本信号机制,
包括动作电位模式、神经传递和血管收缩之间的相互作用2)
确定Ob-HTN中神经血管转导过度的新机制,以及3)提供
在SNA升高和夸大的其他患者人群中进行研究的途径
血管收缩,包括睡眠呼吸暂停、代谢疾病和心力衰竭。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher M Hearon其他文献
Christopher M Hearon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher M Hearon', 18)}}的其他基金
Sympathetic neural patterns and transduction in obesity-associated hypertension
肥胖相关高血压的交感神经模式和转导
- 批准号:
10247728 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Sympathetic neural patterns and transduction in obesity-associated hypertension
肥胖相关高血压的交感神经模式和转导
- 批准号:
10039251 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure with Preserved Ejection Fraction
射血分数保留的心力衰竭患者运动期间血管、代谢和神经功能异常
- 批准号:
10266745 - 财政年份:2017
- 资助金额:
$ 24.9万 - 项目类别:
Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure with Preserved Ejection Fraction
射血分数保留的心力衰竭患者运动期间血管、代谢和神经功能异常
- 批准号:
9327726 - 财政年份:2017
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 24.9万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 24.9万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 24.9万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 24.9万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 24.9万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 24.9万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 24.9万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 24.9万 - 项目类别: